Mimedx (MDXG) Asset Writedowns and Impairment (2016 - 2026)

Mimedx (MDXG) has 8 years of Asset Writedowns and Impairment data on file, last reported at $1.5 million in Q1 2026.

• For the quarter ending Q1 2026, Asset Writedowns and Impairment rose 97.3% year-over-year to $1.5 million; the trailing twelve-month figure through Mar 2026 stood at $7.2 million (up 536.5% YoY), and the FY2025 full-year result was $6.5 million, up 994.96% from the prior year.
• Asset Writedowns and Impairment eased to $1.5 million in Q1 2026, from $3.4 million in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $3.4 million in Q4 2025 to a low of -$279000.0 in Q3 2024.
• A 5-year average of $860533.3 and a median of $426000.0 in 2022 frame the typical range for Asset Writedowns and Impairment.
• Peak annual rise in Asset Writedowns and Impairment reached 48200.0% in 2023, while the deepest fall reached 83.9% in 2023.
• Tracing MDXG's Asset Writedowns and Impairment over 5 years: stood at $3000.0 in 2022, then soared by 48200.0% to $1.4 million in 2023, then slumped by 68.67% to $454000.0 in 2024, then soared by 641.41% to $3.4 million in 2025, then plunged by 56.51% to $1.5 million in 2026.
• Business Quant data shows MDXG's Asset Writedowns and Impairment at $1.5 million in Q1 2026, $3.4 million in Q4 2025, and $2.1 million in Q3 2025.